Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART
Stopped early · Phase 2
Conditions studied: HIV Seropositivity, HIV Infection
In brief
This is an open-label, prospective, randomized, controlled study of the safety and efficacy including clinical, immunologic, and virologic assessments of adding Ampligen to "HAART" in HIV infected patients with CD4 counts \>300 and HIV-1 plasma RNA \>500 and \<30,000 copies/ml (PCR).
Key facts
- Study ID
- NCT00035581
- Run by
- AIM ImmunoTech Inc.
- People needed
- 16
- Starts
- 2001-05-01
- Expected to finish
- 2005-09-01
- Last updated by the study team
- 2013-04-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Orange County Center for Special Immunology — Fountain Valley, California, United States
- Circle Medical Center — Norwalk, Connecticut, United States
- Dupont Circle Physicians Group — Washington D.C., District of Columbia, United States
- Julia Torres, MD — Fort Lauderdale, Florida, United States
- Scott Ubillos, MD — Tampa, Florida, United States
- St. Michael's Medical Center — Newark, New Jersey, United States
- W. Chris Woodward, DO — Reading, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.